3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
13
Myelodysplastic Syndromes
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Hodgkin Disease
7
Leukemia, Biphenotypic, Acute
5
Burkitt Lymphoma
5
Lymphoma, Non-Hodgkin
4
Hematologic Neoplasms
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neuroblastoma
3
Neoplasms
3
Leukemia, Myelomonocytic, Chronic
3
Rhabdomyosarcoma
2
Myeloproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
2
Teratoma
1
Solid Tumors
1
Sarcoma
1
Recurrence
1
Myelodysplastic-Myeloproliferative Diseases
1
Multi-centric Castleman's Disease
1
Malignant mesenchymal tumor
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Interventions
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Filgrastim
×
90 days
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled